During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

Novartis Ag (NYSE: NVS) Q4 2024 Earnings Call Jan 31, 2025, 8:00 a.m. ET ...

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved a ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

Pharma giant Novartis comfortably beat market forecasts with its fourth-quarter results on Friday, with the Swiss firm ...

Despite the currency market anxiety, stocks pushed higher - with index futures adding to Thursday's Wall Street gains as the ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...